Live
- Flawless Execution: Driver Tenure Solution Achieves Two Years of Zero Production Incidents
- TGBIE extends scholarship deadline to Nov 30
- Leading Data Analytics Expert Boosts Financial Services with Advanced Reports and Dashboards for Hedging and Asset Allocation
- 26 Young India Integrated Resi Schools to come up in State
- BGT 2024-25: Bumrah picks five as India take 46-run lead after bowling out Australia for 104
- Thrilling experience: KV students extract DNA from bananas
- BSP to hold maha dharna on Dec 1
- Telangana Jagruthi to submit report to BC Commission
- John Abraham opens up about his new business venture at Indian Racing Festival
- Sri Chaitanya students take out rally
Covaxin could be back-up for now, says AIIMS chief
Covaxin could be back-up for now, says AIIMS chief
Bharat Biotech's coronavirus vaccine, which is still undergoing clinical trial, is likely to be the ‘back-up’ vaccine in the coming days, Dr Randeep Guleria, the chief of Delhi's All-India Institute of Medical Sciences, said on Sunday as two vaccines got emergency approval from the country's drug regulator
New Delhi: Bharat Biotech's coronavirus vaccine, which is still undergoing clinical trial, is likely to be the 'back-up' vaccine in the coming days, Dr Randeep Guleria, the chief of Delhi's All-India Institute of Medical Sciences, said on Sunday as two vaccines got emergency approval from the country's drug regulator.
Politics has started over the approval to Covaxin, with several Opposition parties pointing out that the vaccine was approved without the full process.
Congress's Shashi Tharoor tweeted, "The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime".
"I feel that in the coming days it is the Serum Institute vaccine that will be the main vaccine, Bharat Biotech only a backup for emergency use in case of reinfection," Dr Randeep Guleria said.
"By that time, they will get their dosage ready and by the time they will get the data which will be able to show that the phase 3 data is robust and they have enough events to show that it is efficacious and it is safe, we will be able to have that vaccine available. But the first few weeks, it will be the serum institute vaccine which will be rolled out. It has 50 million doses available," Dr Guleria said.
Covaxin, the clinical trial of which is being conducted in collaboration with the Indian Council of Medical Research, has completed only its I and II phase trials.
